Long-acting medications for the hyperkinetic disorders -: A systematic review and European treatment guideline
Long-acting medications for the hyperkinetic disorders -: A systematic review and European treatment guideline
复制标题
DOI：
10.1007/s00787-006-0549-0
复制
发表时间：
2006-12-01
影响因子：
6.4
通讯作者：
Taylor, Eric
中科院分区：
文献类型：
--
作者：
Banaschewski, Tobias;Coghill, David;Taylor, Eric
本文报告了一项关于长效药物治疗ADHD和多动症的已发表和未发表数据的系统性综述，给出了缓释兴奋剂制剂和托莫西汀（ATX）的效应量和治疗数量。来自几个欧洲国家的一个专家小组利用该审查对这些药物的实际使用提出了建议，并报告了结论：（1）应提供和使用长效制剂;（2）它们不应取代短效药物（由于费用和剂量灵活性的原因，这将是许多儿童的初始治疗）。需要个体化的临床选择。(3)应提供ATX和缓释兴奋剂制剂。选择将取决于具体情况，并提出了详细的建议。
A systematic review of published and unpublished data on the use of long-acting medications in ADHD and hyperkinetic disorder is reported, giving effect sizes and numbers-to-treat for extended-release stimulant preparations and atomoxetine (ATX). A panel of experts from several European countries used the review to make recommendations about the use of these drugs in practice, and conclusions are reported: (1) Long-acting preparations should be available and used; (2) They should not replace short-acting drugs (which will be the initial treatment for many children for reasons of cost and flexibility of dosing). Individual clinical choice is needed. (3) Both ATX and extended-release preparations of stimulants should be available. The choice will depend upon the circumstances, and detailed recommendations are made.